Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luseogliflozin added to metformin in Caucasian adults with type 2 diabetes mellitus
ISRCTN39549850Phase 3Completed
- Sponsor
- Servier
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of luseogliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Servier. Primary endpoint: Change in HbA1c from baseline to Week 12. Started Feb 2019; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ISRCTN39549850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN39549850.